(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
5 VIPs That Changed Style - 2Brazil's ex-president Bolsonaro operated on for hernia
- 3A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- 4Experts who once backed 'shaken baby' science now fight to free imprisoned caregivers
- 5Israel, Gulf states report fresh missile and drone attacks
- French and Malaysian authorities are investigating Grok for generating sexualized deepfakes
- 23 Most Amusing Messages At any point Sent Among Kids and Their Folks
- It Shouldn’t Be Here: Rescuers Race to Save Whale Stranded in Rare Spot
- Schools to start reopening after Nigeria mass abduction
- I visited every country by 25. Antarctica showed me how much I still hadn't seen.
- Illumina unveils dataset to speed up AI-powered drug discovery
- Home Security Frameworks with Shrewd Elements
- Make your choice for the bird that catches your heart!
- Down to earth Manual for A Modest Hyundai Ioniq Electric for Seniors
